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Advanced glycation end products and mortality in hemodialy- ance between oxidants and antioxidants and the im-
sis patients. muno-inflammatory system are all thought to play a role.
Background. Advanced glycation and oxidation end prod- More specifically, chronic uremia is characterized by theucts (AGEs) cause oxidative stress and trigger cytokine driven
accumulation of advanced glycation end products (AGEs)inflammatory reactions in vitro. The net effects on markers of
as well as an activation of the acute phase response,inflammation and acute phase proteins in vivo as well as their
influence on survival in hemodialysis patients are unknown. for which C-reactive protein (CRP) is the prototype in
Methods. We conducted a cross-sectional study in 312 stable humans. AGEs are diverse fluorescent and non-fluores-
hemodialysis patients and analyzed the interrelationships of cent compounds that are formed in complex not yet fullyAGEs and C-reactive protein (CRP) and their predictive effect
understood reactions starting with the non-enzymaticon all-cause as well as cardiovascular mortality. Mortality was
monitored prospectively over a period of 32 months. AGEs reaction of reducing sugars or other carbonyl compounds
were determined by measuring total serum fluorescent AGEs with free amino groups of proteins. Only a few physiolog-
(AGE-fl) and Nε-(carboxymethyl)-lysine (CML). ically occurring AGEs have been characterized chemi-
Results. The levels of AGE-fl, CML and CRP were 3.2-, 3.8-
cally, such as Nε-(carboxymethyl)-lysine (CML), a color-and 10-fold higher as compared to healthy controls. AGE-fl and
less and nonfluorescent compound [1]. AGEs accumulateCML levels correlated significantly with each other but not with
CRP or serum albumin. Patients with high (above median values) during aging and in the course of many degenerative
AGE-fl or CML levels (109  103 AU and 1.4 g/mL, respec- diseases [2]. Makita and co-workers first noted in 1991
tively) had a significant better survival than those with low that end-stage renal disease patients had dramatically in-(below median values) AGE-fl or CML levels. Patients with
creased serum levels of unspecific AGE-modified pep-high CRP levels (above 7.7 mg/Lmedian value) had a better
tides [3]. Meanwhile, numerous studies measuring levelssurvival than those with low CRP (below median value) when
AGE-fl or CML levels were high in parallel. of total unspecific AGEs, AGE-dependent fluorescence,
Conclusions. In contrast to in vitro data and to current hy- CML and in particular pentosidine have confirmed these
potheses, the presence of high serum AGEs, as measured by
results [4, 5]. Since the kidney has been postulated to beAGE-fl and CML, were not linked to increased mortality. Sta-
responsible for the removal of AGEs [6, 7], the accumu-tistically, high serum AGEs partly overcame the negative im-
pact of the acute phase response on mortality in hemodialysis lation of AGEs in chronic renal insufficiency has been
patients. Whether the benefit of high serum AGEs is an epi- partly attributed to the progressive loss in renal function.
phenomenon or reflects a better nutritional support needs fur- On the other hand, increased de novo generation duether studies.
to enhanced oxidative stress and accumulation of reac-
tive precursors such as dicarbonyls also seem to be impli-
cated [8].
The causes for the high frequency of cardiovascular
Advanced glycation end-products may lead to pro-disease and high incidence of cardiovascular mortality
gression of atherosclerosis by interaction with receptorsin dialysis patients are multifactorial in origin. Distur-
that induce production of free oxygen radicals followedbances in the carbohydrate and lipid metabolism, the bal-
by a release of inflammatory cytokines in different cell
types [9, 10] such as interleukin-6 (IL-6), ultimately lead-
ing to the production of CRP by the liver. A recent ob-Key words: inflammation, C-reactive protein, AGE, carboxymethyl ly-
sine, hemodialysis, cardiovascular disease, dialysis, uremia. servation suggested that glycoaldehyde generated by the
myeloperoxidase-H2O2-chloride system involving acti-Received for publication August 23, 2001
vated phagocytes might lead to CML production, andand in revised form February 1, 2002
Accepted for publication February 20, 2002 thereby play an important role in tissue damage at sites of
inflammation as encountered in atherosclerosis. Besides 2002 by the International Society of Nephrology
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the classical pathway, CML may be formed by glyoxal phy. Angina pectoris was diagnosed when either a stress
test was positive and/or a coronary stenosis 75% ofgenerated during lipid peroxidation or glucose autoxida-
tion [11, 12]. Moreover, co-staining of CML and macro- luminal diameter was found by coronary angiography.
Peripheral vascular disease was diagnosed by the presencephages was found in atherosclerotic lesions where CRP
is deposited as well [13]. It also has been proposed that of claudicatio and diminished pulses on clinical examina-
tion combined with duplex sonography or angiography.CRP may play a part in the recruitment of monocytes
during atherosclerosis [14]. While the finding of CRP in Cerebral vascular disease was defined as a stroke or his-
tory of transient ischemic attacks and positive findingsthe atherosclerotic lesion is of yet unclear pathobiologi-
cal meaning, the predictive association between serologi- in computed tomography or magnetic resonance im-
aging, or an acute functional deficit lasting for 24 hourscal CRP and myocardial events, cardiovascular mortal-
ity, ischemic stroke and peripheral vascular disease has or less. A patient was considered to have vascular disease
(VD) if at least one of these three defined diseases wasbeen extensively described in the general population
[15]. We demonstrated that elevated CRP was the most present.
Smoking was defined on the basis of current smokingpowerful predictor of all-cause and cardiovascular mor-
tality in hemodialysis patients [16]. or previous habitual smoking. Hypertension was defined
as a predialysis systolic blood pressure 140 mm Hg orIn our current study, we hypothesized that circulating
AGEs may promote the inflammatory status seen in a diastolic pressure 90 mm Hg or the use of antihyper-
tensive drugs. Diabetes was defined by glucose values ofhemodialysis patients [17], subsequently leading to high
concentrations of CRP in serum and to cardiovascu- 200 mg/dL and higher at any time or fasting glucose
values 126 mg/dL or the use of insulin or oral antidia-lar mortality. We therefore investigated the relationship
between AGEs and CRP, and analyzed whether total betic drugs.
serum fluorescent AGEs (AGE-fl) and CML were pre-
Follow-up studydictors of overall and cardiovascular mortality in hemo-
dialysis patients. Data of all hemodialysis patients from the original
cohort were followed for analysis of mortality. Date and
cause of death were evaluated from records and from
METHODS
interviews with the physicians in the outpatient dialysis
Study population centers. Causes of death were classified as mortality due
to cardiovascular events (myocardial infarction, con-A total of 312 Caucasian patients on chronic hemodial-
ysis treatment from the dialysis unit of the University gestive heart failure, sudden death and stroke) and non-
cardiovascular events (infection, neoplasma, unknownClinic of Wu¨rzburg and three other outpatient dialysis
centers were prospectively observed for 32 months, from causes).
August 1997 until April 2000. The study was carried out
Sampling procedure and laboratory analysisaccording to the principles of the Declaration of Helsinki.
All patients gave their informed consent before entering Blood samples were collected on ice (4C) prior to
initiation of the hemodialysis session and prior to heparinthe study, and the study protocol was approved by the
appropriate institutional review board. Data on age, sex, administration and were centrifuged within 60 minutes
after collection. Measurements of CRP, albumin, fibrin-body mass index (BMI; weight in kilograms divided by
the square of the height in meters), primary renal disease ogen, apolipoproteins and lipids were performed on
fresh samples. Serum samples for measurement of AGE(diabetes, hypertension, other), time since initiation of
hemodialysis (years) and weekly dialysis time (hours/ were stored at 70C. The serum concentration of CRP
was measured by a nephelometric immunoassay (NAweek) were recorded. Sixty middle-aged healthy subjects
served as controls. Latex CRP Reagent; Behring Institute, Marburg, Ger-
many). Creatinine and blood urea nitrogen (BUN) were
Baseline examination determined by enzymatic methods. Measurement of se-
rum albumin was carried out using the bromocresolPatients were examined at baseline and no clinical signs
of overt infection were present. The presence of coronary green method. Fibrinogen was measured by the throm-
bin time method (Clauss) in a blood sample anticoagu-artery disease (CAD), peripheral vascular disease (PVD)
and cerebral vascular disease (CVD) was assessed by lated with 3.8% sodium citrate. Apolipoproteins A-1
(apo A-1), A-2 (apo A-2) and B (apo B) were measuredinterviews and by reviewing clinical charts. Patients with
a history of myocardial infarction or angina pectoris were by nephelometric methods. Total cholesterol and triglyc-
erides were measured by enzymatic-colorimetric meth-classified as having coronary artery disease. A previous
myocardial infarction was defined by the presence of ods (cholesterol CHOD-PAP, triglycerides PAP; Roche
Diagnostics Mannheim, Mannheim, Germany). High-chest pain, a confirmatory electrocardiogram, enzyme
courses or pathological findings from coronary angiogra- density lipoprotein cholesterol (HDL-C) was measured
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Table 1. Clinical and laboratory characteristicsafter precipitation with MgCl2 and low-density lipoprotein of hemodialysis patients and controls
cholesterol (LDL-C) was calculated using the Friedewald
All patients Controlsformula (in patients with triglycerides 400 mg/dL).
Characteristics (N  312) (N  60)
Age years 62.7	12.8 42.9	11aAGE measurements
range 27–86 30–67
In thawed serum samples we assessed CML concentra- Gender (M/F) % 54/46 53/47
BMI kg/m2 24.1	4.6 25.2	3.3ations and AGE-fl. CML was measured in triplicate with
CRP mg/L 16.3	25.1 1.6	2.4acompetitive ELISA using monoclonal antibody against
Albumin g/L 40.5	4.1 47.3	2.4a
CML (Alteon Inc., New York, NY, USA) developed by Fibrinogen g/L 4.1	1.3 2.8	0.5a
AGE-fl AU (103) 108.7	32.1 33.8	5.2aRoche Diagnostics as described earlier [18]. Prior to
CML lg/mL 1.44	0.61 0.38	0.1adetermination of CML content, serum was digested with
Creatinine mg/dL 9.5	2.7 1.0	0.1a
proteinase K (1 mg/mL) for three hours at 37C. Reac- BUN mg/dL 63	17 16	4a
Apo B mg/dL 100	28 101	21ation was stopped by adding 2 mmol/L phenylmethylsul-
Apo A-1 mg/dL 127	23 166	27afonyl fluoride (PMSF; Roche Diagnostics). To estimate
Apo A-2 mg/dL 33	14 38	12a
the absolute CML concentration of digested and diluted Cholesterol mg/dL 194	47 187	33a
Triglycerides mg/dL 227	181 166	121aserum (20-fold) N-(carboxymethyl)amino-caproic acid was
LDL-C mg/dL 116	36 98	28aused as the standard (Alteon, Inc.). Microtiter enzyme-
HDL-C mg/dL 35	13 58	15a
linked immunosorbent assay (ELISA) plates were incu-
Data are given as mean 	 SD. Abbreviations are: BMI, body mass index;bated with AGE-bovine serum albumin (AGE-BSA; 100 CRP, C-reactive protein; AGE-fl, fluorescent advanced glycation end-products;
CML, Nε-(carboxymethyl)-lysine; BUN, blood urea nitrogen; Apo, apolipopro-ng/well) for one hour followed by three washing steps.
tein; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipopro-Thereafter, serum and CML standards were incubated tein cholesterol.
a P  0.0001with peroxidase-conjugated monoclonal antibody against
CML for two hours. After three washing steps color
reaction was induced with 2,2
-azino-di-3-ethylbenzthia-
zoline-sulfonic acid (Roche Diagnostics). Absorbance
given. Data are expressed as mean 	 SD. P values lesswas read in a microtiter ELISA plate reader (Multiscan
than 0.05 were considered significant. Data analysis wasAscent; Labsystems, Helsinki, Finland) at 405 nm (refer-
performed using the SPSS/PC package (SPSS Inc., Chi-ence 603 nm). All steps were carried out at room temper-
cago, IL, USA).ature (RT). Results were expressed as g CML/mL.
Fluorescent AGE intensity of 50-fold diluted serum
samples was measured in triplicate at 460 nm after excita- RESULTS
tion at 355 nm, using a fluorescence reader (Victor 1; Clinical and biochemical characteristics
Wallace, Turku, Finland) [19]. Serum AGE-fl was ex-
Twenty-eight percent of the 312 patients suffered frompressed as relative fluorescence intensity in arbitrary
diabetes mellitus type 1 or 2. The primary renal diagnosisunits (AU). Hemolytic sera were excluded from AGE
was split among diabetes (23%), hypertension (33%)measurements (N  10). For five other patients serum
and other causes. The mean time on dialysis was 6.1 	was not sufficient to perform both CML and AGE-fl
4.8 years (range 3 to 299 months). Weekly dialysis timemeasurements in triplicates, and so for these patients
was 12.5 	 1.4 hours. Hemodialysis treatment was per-only CML measurements were done.
formed using conventional bicarbonate-buffered dialy-
Statistical analysis sate in all patients. Dialyzer membranes used were made
of polysulfone (47%), polyamide (14%), cellulose (38%)Comparisons between all pairs were performed using
and other materials (1%). Dialyzer membranes with anthe Mann-Whitney U test for non-normally distributed
ultrafiltration coefficient 20 mL/(mm Hg  h) werevariables, comparisons between more than two groups
considered as high flux, all those below this value as lowwere performed using the Kruskal-Wallis H test. Bivari-
flux membranes. Based on this definition 72% of allate regression and correlation analyses were performed
patients were dialyzed with low flux and 28% with highbetween all available data by using the Spearman rank
flux membranes. Medication of patients included antihy-method. The cumulative incidence of death during fol-
pertensive drugs (64%), phosphate binders (calcium ace-low-up was estimated by the Kaplan-Meier method. Rel-
tate or carbonate and/or aluminum hydroxide), vitaminative risk of mortality for different parameters was esti-
B, C and D supplementation, epoetin, iron gluconate,mated using the Cox proportional hazards model.
aspirin (37%), and lipid lowering agents (19%). AspirinRelative risks and their 95% confidence intervals (95%
was given in a dose of 100 to 300 mg/day.CI) were calculated with the use of the estimated regres-
Table 1 depicts clinical and biochemical characteristicssion coefficients and their standard errors in the Cox
regression analysis. In addition, chi-square statistics were of patients and controls. Hemodialysis patients were sig-
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Table 2. Clinical and laboratory characteristics of patients according to serum levels of AGE-fl and CML (below and above the median)
AGE-fl CML
median median median median
Characteristics (N  148) (N  149) (N  151) (N  151)
Age years 64.4	12.7 60.9	13.1b 63.7	11.3 61.6	14.3
BMI kg/m2 24.5	4.8 24.0	4.1 24.7	4.4 23.5	4.5b
CRP mg/L 17.6	25.4 14.3	20.6 18.1	25.9 13.4	19.5a
Albumin g/L 39.7	4.5 41.3	3.4b 39.8	4.4 41.2	3.6a
Fibrinogen g/L 4.1	1.2 4.1	1.3 4.2	1.2 4.0	1.3a
AGE-fl AU (103) — — 102.5	30.6 115.3	32.5b
CML lg/mL 1.31	0.57 1.56	0.62b — —
Creatinine mg/dL 9.0	2.9 10.0	2.4 8.8	2.5 10.3	2.7c
BUN mg/dL 62	18 64	17 60	16 66	18b
Vascular disease 42 37 45 34a
Diabetes 29 28 38 19c
Smoking 16 25 19 22
Aspirin medication 37 40 42 35
High flux membrane 30 23 30 25
Data are given as mean 	 SD. Data of AGE-fl are given in arbitrary units (AU)  103 with a median of 109; data of CML are given in g/mL with a median of
1.4. Vascular disease, diabetes, smoking, aspirin medication, high flux membrane are given in %. Abbreviations are in Table 1.
a P  0.05, bP  0.01, cP  0.001 between AGE-fl and CML above and below the median
nificantly older and had a lower BMI than controls. In high AGE-fl were significantly younger and had higher
both groups gender was equally distributed. Forty per- albumin and CML levels than patients with low AGE-fl.
cent of patients suffered from vascular disease (25% The same incidences of vascular disease, diabetes and
CAD, 14% PVD, 11% CVD) and 65% had hyperten- smoking were observed.
sion. Smoking habits were similar in patients and controls In the group with high CML levels a lower BMI, lower
(21 vs. 32%). Patients had considerably higher CRP CRP and fibrinogen levels, but higher albumin, creati-
(10.2-fold) and CML (3.8-fold) levels and higher AGE-fl nine and BUN levels and AGE-fl were found. The inci-
(3.2-fold) than controls. In addition, they had higher dence of vascular disease and diabetes was significantly
levels of fibrinogen, cholesterol, triglycerides, LDL-C, lower. No differences in smoking habits were seen. In
but lower levels of albumin, apo B, apo A-1, apo A-2 all four subgroups aspirin medication and high flux mem-
and HDL-C. Smokers (N  65) had significantly higher brane use were similar.
AGE-fl (119.0 	 32.9 vs. 105.8 	 31.6 AU  103, P  Patients with very low serum albumin (35 g/L, N 
0.01) but similar CML (1.51 	 0.65 vs. 1.43 	 0.60 g/ 28%) also had very low AGE-fl (97.8 	 28.4 vs. 109.7 	
mL) levels compared to non-smokers (N  247). There 32.3  103 AU, P  0.055), CML (1.07 	 0.56 vs. 1.48 	
was a trend toward higher CRP levels in smokers (21.4	 0.61 g/mL, P  0.001) in comparison to those patients
31.6 vs. 14.9 	 23.5 mg/L) but this was not statistically with albumin 35 g/L.
significant. In controls no differences were found be-
tween smokers and non-smokers concerning AGE-fl and Analysis of mortality rates according to high and low
CML levels. AGE-fl, CML and CRP
Diabetic patients (N  87) had a higher BMI (25.0 	
During the follow-up period of 32 months 34% of pa-4.7 vs. 23.7	 4.4 kg/m2, P 0.01) and a higher incidence
tients (N  105) had died, which corresponds to anof hypertension (74 vs. 61%, P  0.05), CAD (47 vs.
annual mortality rate of 13%. Forty-seven percent were17%, P  0.001), PVD (34 vs. 6%, P  0.001) and
cardiovascular and 53% were non-cardiovascular deaths.CVD (17 vs. 8%, P  0.05) as compared to non-diabetic
At the beginning of the observation period the calculatedpatients (N 225). Taken together, 69% of diabetic and
mean survival time per patient was 25.1 months. Pres-28% of non-diabetic patients had vascular disease (P 
ence of vascular disease (VD) and diabetes decreased0.001). While smoking habits, CRP (16.3	 22.2 vs. 16.3	
survival significantly [22.3 months vs. 27 months for VD26.3 mg/L), AGE-fl (107.7 	 27.6 vs. 108.8 	 33.8 AU 
(P  0.01), 22.6 months vs. 26 months for diabetes (P 103) and fibrinogen levels were similar, albumin and
0.001)].CML (1.24 	 0.55 vs. 1.53 	 0.62 g/mL, P  0.001)
The all-cause as well as cardiovascular mortality rateslevels were lower in diabetic patients as compared to
were significantly higher in patients with low AGE-fl asnon-diabetic patients.
compared to those with high AGE-fl (44 vs. 23%, P 
Clinical and biochemical characteristics of patients 0.0001, and 20 vs. 12%, P  0.05, respectively). Thus,
according to AGE-fl and CML levels the expected lifespan for patients with high AGE-fl at
time zero increased from 22.8 months (for patients withTable 2 shows the data of patients divided according
to high and low AGE-fl and CML levels. Patients with low AGE-fl) up to 27.8 months (Fig. 1A).
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Fig. 1. Kaplan-Meier estimates of survival during follow-up with regard to all-cause mortality in relation to high (↑, above median values) or low
(↓, below median values) fluorescent advanced glycation end-products (AGE-fl; A) and Nε-(carboxymethyl)-lysine (CML; B).
Table 3. Relative risks of mortality after 32 months according to quartiles of baseline serum concentrations of CRP, AGE-fl and CML
All-cause mortality Cardiovascular mortality
Relative risk Relative risk
Risk factor N (95% CI) P value (95% CI) P value
CRP mg/L
3.4 79 1 1
3.4–7.7 76 1.96 (0.97–3.99) 0.06 1.61 (0.61–4.22) 0.34
7.8–17.2 77 2.18 (1.09–4.39) 0.028 1.31 (0.48–3.62) 0.60
17.2 78 6.09 (3.23–11.46) 0.001 5.20 (2.24–12.08) 0.0001
AGE-fl AU (103)
83.7 74 1 1
83.7–109.0 74 0.97 (0.60–1.58) 0.91 0.67 (0.32–1.38) 0.28
109.1–131.0 74 0.53 (0.30–0.92) 0.024 0.53 (0.25–1.11) 0.09
131.0 73 0.36 (0.19–0.67) 0.001 0.28 (0.11–0.70) 0.007
CML lg/mL
0.99 74 1 1
0.99–1.40 76 0.71 (0.42–1.19) 0.19 1.16 (0.55–2.44) 0.71
1.41–1.86 76 0.51 (0.29–0.89) 0.019 0.50 (0.20–1.26) 0.14
1.86 74 0.61 (0.36–1.05) 0.08 0.81 (0.36–1.84) 0.62
A higher all-cause mortality rate also was observed in as well as death caused by cardiovascular events in-
creased with each quartile of baseline concentration ofpatients with low CML levels as compared to those with
high CML levels (38 vs. 27%, P  0.05; Fig. 1B). The CRP, while for AGE-fl it decreased. For CML a similar
trend was present for all-cause mortality. Thus, patientsmean survival time was 24.1 and 26.5 months, accord-
ingly. There was a tendency toward higher cardiovascu- in the highest CRP quartile had a 6.1-fold higher risk
for all-cause and a 5.2-fold higher risk for cardiovascularlar mortality (19 vs. 12%, P  0.08) in the former group,
as compared to the latter. mortality during follow-up than those in the lowest quar-
tile. By contrast, patients in the highest AGE-fl quartileFor CRP, the opposite was observed. All-cause and
cardiovascular mortality rates were significantly higher had a 0.36-fold lower risk for all-cause and a 0.28-fold
lower risk for cardiovascular mortality than those in thein patients with high CRP levels as compared to those
with low CRP levels (46 vs. 21%, P  0.0001, and 21 vs. lowest AGE quartile.
By univariate Cox regression analysis, various factors11%, P  0.01, respectively). This observation was con-
firmed when comparing the relative risk of all-cause and such as age, pre-existing vascular disease, presence of dia-
betes, CRP, albumin, fibrinogen, apolipoprotein A-1 (apocardiovascular mortality of patients divided in quartiles
(Table 3). For CRP the relative risk of death in general A-1), apo A-2 and AGE-fl were significantly associated
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Table 4. Predictiors of overall mortality after 32 months in hemodialysis patients by the univariate and multivariate Cox regression analysis
Univariate Cox regression analysis Multivariate Cox regression analysis
Variable Units 2 Relative risk P value 2 Relative risk P value
Age years 29.30 1.05 0.001 8.82 1.03 0.004
Pre-existing CVD Ref  no CVD 12.39 1.97 0.001 9.24 1.93 0.002
Diabetes Ref  nondiabetic 9.08 1.81 0.003 — — NS
CRP mg/L 36.60 1.13 0.001 7.45 1.10 0.003
Albumin g/L 77.42 0.15 0.001 36.48 0.19 0.001
Fibrinogen g/L 5.99 1.20 0.014 — — NS
Apo A-1 mg/dL 13.04 0.98 0.001 — — NS
Apo A-2 mg/dL 9.06 0.97 0.001 — — NS
AGE-fl AU 8.73 1.00 0.003 — — NS
Fig. 2. Kaplan-Meier estimates of survival during follow-up with regard to all-cause mortality in relation to groups of high (↑, above median
values) or low (↓, below median values) C-reactive protein (CRP) and AGE-fl (A) or CML (B) values.
with all-cause mortality while sex, BMI, smoking, hyper- (from 18.5 to 26.3 months mean survival) was noticed.
Patients with low CRP and high AGE-fl values had thetension, CML, lipids and apo B were not. The multivari-
ate stepwise regression analysis demonstrated that age, best survival (29.2 months mean survival). No significant
difference in survival was present between the high andpre-existing vascular disease, CRP and albumin were
independent predictors of all-cause mortality (Table 4). low AGE-fl groups if CRP was low.
Comparing the characteristics of the two AGE-fl/CRPDiabetes, fibrinogen, apo A-1, apo A-2 and AGE-fl lost
their significance as survival factors in the multivariate groups with best and worst survival rates, the incidence
of diabetes, smoking habits, aspirin medication and highCox model.
flux membrane use were similar (Table 5). The group
Analysis of mortality rates according to various with the worst survival was older and had lower serum
combinations of high and low CRP and albumin, creatinine and BUN levels. With decreasing
AGE-fl/CML levels survival the incidence of vascular disease increased con-
sistently from 30 to 46%, but no significant level wasSince AGEs and CRP showed the opposite influence
on overall and cardiovascular mortality, we analyzed reached. Comparing the two groups with low CRP and
low or high AGE-fl albumin and creatinine increasedgroups of various combinations of both parameters. Pa-
tients with high CRP and low AGE-fl had the worst with increasing AGE-fl (Table 5).
The same trend of increased survival was seen if com-survival (Fig. 2A). If in parallel to high CRP levels
AGE-fl was high, a dramatic increase in the survival rate paring the low CML/high CRP-group with the high
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Table 5. Clinical and laboratory characteristics of patients divided in four groups according to AGE-fl and CRP
above or below the median with decreasing survival from left to right
AGE-fl  median AGE-fl  median AGE-fl  median AGE-fl  median
 CRP  median  CRP  median  CRP  median  CRP  median
Characteristics (N  74) (N  72) (N  73) (N  76)
Age years 58.6	13.7 63.0	13.1 62.9	12.2 66.0	12.2a
BMI kg/m2 23.2	3.5 24.7	4.8 24.7	4.5 24.2	4.7
CRP mg/L 3.4	1.9 3.9	2.1 25.3	24.8 30.6	30.2
Albumin g/L 42.1	3.0 41.5	2.8 40.5	3.6 37.9	5.0a,c
Fibrinogen g/L 3.5	0.8 3.6	0.8 4.7	1.4 4.6	0.1
AGE-fl AU (103) 137.1	18.4 81.7	16.1 133.4	19.4 82.8	18.5
CML lg/mL 1.63	0.55 1.37	0.56 1.50	0.68 1.24	0.59
Creatinine mg/dL 9.9	2.4 9.4	3.0 10.1	2.3 8.7	2.8a,c
BUN mg/dL 66	17 65	15 61	16 58	19b
Vascular disease 30 37 45 46
Diabetes 27 27 28 32
Smoking 23 12 27 20
Aspirin medication 32 32 47 42
High flux membrane 27 32 19 29
Data are given as mean 	 SD. Data of AGE-fl are given in arbitrary units (AU)  103 with a median of 109; data of CML are given in g/ml with a median of 1.4.
Vascular disease, diabetes, smoking, aspirin medication, high flux membrane are given in %.
a P  0.01, b P  0.05 for AGE-fl   CRP  median (last column) vs. AGE-fl   CRP  median (first column)
c P  0.001, d P  0.05 for AGE-fl   CRP  median (last column) vs. AGE-fl   CRP  median (third column)
Table 6. Clinical and laboratory characteristics of patients divided into groups according to CML and CRP
above or below the median with decreasing survival from left to right
CML  median CML  median CML  median CML  median
 CRP  median  CRP  median  CRP  median  CRP  median
Characteristics (N  84) (N  66) (N  66) (N  84)
Age years 59.7	14.7 62.4	11.7 64.0	13.5 64.7	11.0
BMI kg/m2 22.9	4.0 25.0	4.3 24.3	5.0 24.4	4.5b
CRP mg/L 3.6	2.1 3.7	2.1 25.8	24.1 29.6	30.2
Albumin g/L 42.0	3.0 41.4	3.0 40.1	3.9 38.6	4.9a,d
Fibrinogen g/L 3.4	0.8 3.6	0.9 4.6	1.5 4.6	1.2
AGE-fl AU (103) 115.8	33.1 102.0	30.7 114.7	31.8 102.8	30.6
CML lg/mL 1.92	0.41 1.00	0.25 1.97	0.45 0.90	0.27
Creatinine mg/dL 10.5	2.7 8.6	2.5 10.1	2.6 8.9	2.6a,d
BUN mg/dL 68	18 63	14 63	18 57	17b
Vascular disease 27 42 42 48b
Diabetes 19 37 18 38b,c
Smoking 21 13 22 24
Aspirin medication 27 39 45 44
High flux membrane 27 33 21 27
Data are given as mean 	 SD. Data of AGE-fl are given in arbitrary units (AU)  103 with a median of 109; data of CML are given in g/ml with a median of
1.4. Vascular disease, diabetes, smoking, aspirin medication, high flux membrane are given in %.
a P  0.001, b P  0.01 for CML   CRP  median (last column) vs. CML   CRP  median (first column)
c P  0.01, d P  0.05 for CML   CRP  median (last column) vs. CML   CRP  median (third column)
CML/high CRP-group, but it did not reach a significant differences were noticed between all groups concerning
smoking habits, aspirin treatment and use of high fluxlevel (Fig. 2B). Again, patients with low CRP had the
best survival no matter how elevated the CML levels. membranes. There was an overall trend toward higher
incidence of vascular disease with decreasing survival.Significant differences were observed between the best
and worst survival rates in terms of higher serum albu-
Aspirin, inflammation and mortalitymin, BUN and creatinine levels and lower incidence of
diabetes and vascular disease in the group with best Interestingly, patients on aspirin medication had higher
CRP levels (18.2 	 26.0 vs. 15.5 	 24.9 mg/L, P  0.05).survival (Table 6). Again, in the two groups with both low
CRP but different CML levels, albumin and creatinine CRP levels were higher in patients with vascular disease
as compared to those without (19.5 	 29.9 vs. 14.1 	increased when in parallel CML levels increased. By
contrast, a significantly higher percentage of diabetic 21.1 mg/L, P  0.05). Fifty percent of patients under
aspirin treatment had vascular disease compared to 33%patients was present in the group with the worst survival
rate in comparison to the high CML/high CRP-group. No without (P  0.01). AGE-fl (107.8 	 31.9 vs. 109.4 	
Schwedler et al: AGE and mortality in hemodialysis patients308
ment. The results of the present study demonstrate high
levels of serum AGEs in HD patients, thus confirming
earlier reports [20–23]. The main findings of the present
study were that diabetes and vascular disease were linked
to increased mortality, while high (above the median)
serum levels of AGE-fl and CML were not. In parallel,
diabetics or patients with vascular disease didn’t have
increased serum AGE levels. Statistically, high levels of
AGE-fl and CML were even linked to a better survival.
Since high CRP levels were associated with increased
mortality, we addressed the question of how the combi-
nation of high levels of AGE-fl/CML and CRP influ-
enced mortality. For both parameters, AGE-fl and CML,
survival was worst when the combination of low AGE
and high CRP levels coincided. Strikingly, survival in-
creased significantly when AGE-fl increased in the iden-
tical inflammatory setting. A similar, but not statisticalFig. 3. Kaplan-Meier estimates of survival during follow-up with regard
to all-cause mortality in relation to aspirin intake. significant trend was observed for CML.
To explore these unexpected findings we analyzed dif-
ferent factors that may have interfered such as diabetes,
smoking, dialysis membrane use, and aspirin medication.32.3 AU  103) and CML levels (1.42 	 0.57 vs. 1.45 	
The incidence of diabetes was identical in all AGE-fl/0.64 g/mL) were similar in those with or without aspirin
CRP groups, while more diabetics were found in the lowtreatment. When comparing patients with and without
CML/high CRP (highest mortality) as compared to thevascular disease no differences in AGE-fl and CML lev-
high CML/high CRP (lowest mortality) and the highels were observed. Aspirin treatment had no benefit on
CML/high CRP group. Therefore, diabetes may have in-survival (25.0 vs. 24.9 months without aspirin; Fig. 3).
terfered in the CML/CRP subgroups. The similarity of
AGE levels in diabetic and non-diabetic hemodialysisCorrelation between parameters
patients indicates that uremia-associated factors such asA significant correlation was found between AGE-fl
oxidative or -dicarbonyl stress are probably of greaterand CML levels (R  0.25, P  0.001), while a negative
importance for the late stage of the Maillard reactioncorrelation was present between albumin and CRP (R
than glycemic control. In our study diabetic patients had0.37, P  0.001) as well as fibrinogen (R  0.2, P 
even lower CML levels than non-diabetics, a yet unex-0.001). Creatinine and BUN correlated positively with
plained finding already described previously [24]. AGE-fleach other (R 0.46, P 0.001) and with albumin (R
correlated significantly with CML levels showing com-0.38, P  0.001, and R  0.29, P  0.001, respectively),
mon origins of formation [25]. Differences in smokingwhile they correlated negatively with age (R  0.45,
habits and membrane use (percentage of high flux mem-P  0.001, and R  0.26, P  0.001, respectively).
brane use) did not contribute to differences in survival.Between creatinine and CML a positive correlation (R
When comparing clinical parameters in relation to in-0.31, P 0.001) was found. A weak but significant corre-
creasing survival in all groups, consistently higher levelslation also was demonstrated between creatinine and
of serum creatinine, BUN and albumin were found. TheAGE-fl (R  0.16, P  0.01) and age and AGE-fl (R 
significance of protein caloric malnutrition in chronic0.15, P  0.05). No correlation was found between
hemodialysis patients has been emphasized often. Low-AGE-fl and age in controls.
rie, Huang and Lew showed that four of the six most im-
portant predictors of outcome were nutritionally related
DISCUSSION [26]. Serum albumin has been considered to be a key in-
dex of nutritional status, and is commonly used to assessThe present study tested the hypothesis that AGEs
are linked to mortality and cardiovascular disease by ac- malnutrition. However, data show that serum albumin is
dependent on several other factors such as age, fluidtivating the acute phase response in uremia. Serum fluo-
rescent AGEs (AGE-fl) and carboxymethyllysine (CML), overload, capillary leakage, and most importantly in-
flammation [16, 27]. In our study albumin was relatedone specific AGE component, as well as CRP, a promi-
nent acute phase protein, were determined and their to inflammation, as assessed by the inverse correlation
with CRP, but also was positively related to creatinine,effect on all-cause as well as cardiovascular mortality
was studied over a period of more than two years in a which itself was independent of CRP. Creatinine and
CML correlated significantly. Although we were not ablecohort of patients on maintenance hemodialysis treat-
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to reliably determine the actual nutritional status of our of CRP [33]. Further analysis of our data in relation to
aspirin intake revealed that a considerable number ofpatients retrospectively, we speculate that the higher
patients were on aspirin medication but apparently hadcreatinine, albumin and BUN values found in those pa-
no benefit in terms of a better survival. Patients on aspirintients with higher AGE levels all may be indicators of
treatment also had higher CRP levels, another unex-a better nutritional status. Whether high AGE levels in
pected finding in this study. One explanation is that moreserum are due to AGE absorption from food [28] is
patients suffered from vascular disease in the aspirindisputed by others [29] and remains controversial. Thus,
group, which therefore represented a selection of pa-high AGE levels in serum may be an epiphenomenon
tients at a high risk for cardiovascular events. In general,of a better nutritional state.
vascular disease patients do have higher CRP levels. InCertainly, fluorescence is not specific for individual
this context aspirin treatment might be promising sincecompounds and interference with other fluorescent com-
the survival was similar in groups of patients with differ-pounds may occur [19]. However, it may comprise un-
ent cardiovascular risk profiles and CRP levels. We sug-known AGE compounds with physiological impact. The
gest that the aspirin results presented here are typicalphysiological activity of the well characterized AGEs
for a morbid population in which some “expected” re-such as CML, pentosidine or imidazolone is still not
sults are confounded by diseases. It appears that theseunequivocally proven. We also aimed for second line
data represent another example of reverse causality of-evidence by measuring CML, and the results confirmed
ten seen in such patient populations. Only prospectivethose obtained with AGE-fl. Clearly, the findings were
studies may clarify this issue.not in accordance with our expectation and the hypothe-
The present findings demonstrate that the mechanismssis of the study [17] and cannot be extrapolated to other
proposed are not translated into an in vivo clinical situa-AGE compounds. For example, pentosidine shows a
tion. However, it may still be possible that the damagingmuch higher degree of accumulation (approximately
effects of AGEs on the cardiovascular system may be10-fold) and different pathways of AGE-formation may
seen locally in tissues or cells [34] or with other types ofexist in vivo. However, the concentration of pentosidine
AGEs [35]. On the other hand, a recent study foundis 100-fold lower than the concentration of CML. Never-
that pentosidine, a reliable marker of “carbonyl stress,”theless, similar data were obtained in a cohort of patients
was unrelated to intima media thickness and to the num-from southern Italy when pentosidine levels were cor-
ber of atherosclerotic plaques [36]. Furthermore, it isrelated with mortality (C. Zoccali, personal communi-
likely that the blood load of AGEs resembles only acation). A similar and initially conflicting finding was
small fraction of total body AGE content and that therecently reported by Suliman et al, who showed that
serum levels reflect—besides kidney function—partic-
patients with serum homocysteine levels 24 mol/L ular changes in the overall AGE pool (Faist and Erbers-
(above median values) had a significantly better four- dobler, personal communication). Thus, circulating AGEs
year survival rate than those with homocysteine levels may not be an adequate parameter for demonstrating
below the median [30]. The results demonstrated that effects on outcome. Most likely the focus should be on
global nutritional assessment and protein intake as well intracellular AGEs [37–39].
as total plasma cysteine levels influenced total homocys- In summary, our study indicates that low levels of AGEs,
teine levels in hemodialysis patients. Until these results as determined by AGE-fl and CML, were not linked
were published homocysteine was undoubtedly consid- to a better survival rate in hemodialysis patients when
ered to be a strong cardiovascular risk factor in hemodial- observed over a period of 32 months. A correlation to the
ysis patients, a finding that still holds true in the general acute phase response (as determined by CRP) could not
population. The mechanism by which homocysteine ex- be demonstrated, and the hypothesis that high levels of
erts its initial cardiovascular damage was recently pro- CML and AGE-fl may activate an acute phase response
posed to be similar to that of AGEs [31]. Both activators was not demonstrated by serum markers. Whether high
of endothelial dysfunction—homocysteine and AGEs— AGE levels are reflective of a better nutritional support
may signal their action through the transcription factor cannot be clarified at this point. We emphasize that our
nuclear factor-B via generation of oxygen free radicals. results don’t mean that AGEs are “beneficial” per se,
As a result of the initial oxidative stress, multiple genes thus contradicting previously published studies about the
are turned on that induce the generation of cytokines role of AGEs in vascular disease. Rather, our results sug-
(IL-6, IL-8), chemokines (MCP-1, M-CSF) and adhesion gest that serum AGE levels in hemodialysis patients are
molecules (VCAM-1, ICAM-1). These in vitro findings probably not very conclusive when determining cardio-
are strongly supported by a number of experiments. The vascular outcome.
cascade finally may result in an inflammatory response
that can be determined by CRP in serum [32]. ACKNOWLEDGMENTS
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